| Literature DB >> 29899207 |
Yingcong Ma1, Meng Sha2, Shixuan Cheng3, Wang Yao4, Zhongjun Li5, Xian-Rong Qi6.
Abstract
The CD44 protein, as a predominant receptor for hyaluronan (HA), is highly expressed on the surface of multiple tumor cells. HA, as a targeting molecule for a CD44-contained delivery system, increases intracellular drug concentration in tumor tissue. However, due to the weak binding ability of hyaluronan oligosaccharide to CD44, targeting for tumor drug delivery has been restricted. In this study, we first use a HA tetrasaccharide cluster as the target ligand to enhance the binding ability to CD44. A polyamidoamine (PAMAM) dendrimer was modified by a HA tetrasaccharide cluster as a nonviral vector for small interfering RNA (siRNA) delivery. The dendrimer/siRNA nanocomplexes increased the cellular uptake capacity of siRNA through the CD44 receptor-mediated endocytosis pathway, allowing the siRNA to successfully escape the endosome/lysosome. Compared with the control group, nanocomplexes effectively reduced the expression of GFP protein and mRNA in MDA-MB-231-GFP cells. This delivery system provides a foundation to increase the clinical applications of PAMAM nanomaterials.Entities:
Keywords: CD44 protein; cellular uptake; endosome escape; hyaluronic acid tetrasaccharide; polyamidoamine (PAMAM) dendrimer; small interfering RNA
Year: 2018 PMID: 29899207 PMCID: PMC6027316 DOI: 10.3390/nano8060433
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Figure 1Synthetic scheme of polyamidoamine (PAMAM)-gallic acid triethylene glycol (GATG)- hyaluronan tetrasaccharide clusters (HA4).
Figure 2(a) Agarose gel electrophoresis of PAMAM-3GATG-HA4/siRNA and PAMAM-6GATG-HA4/siRNA nanocomplexes at different N/P ratios. (b) Particle size and zeta potential of PAMAM-3GATG-HA4/siRNA and PAMAM-6GATG-HA4/siRNA nanocomplexes at different N/P ratios. siRNA concentration in nanocomplexes was 100 nM. (c) Transmission electron microscopy (TEM) images of PAMAM-3GATG-HA4/siRNA and PAMAM-6GATG-HA4/siRNA nanocomplexes. The scale was 2 μm in the original and 100 nm in the magnified image. (d) Serum stability of nanocomposites at 37 °C for 24 h. Results are expressed as mean ± SD (n = 3).
Figure 3(a) Effects of vectors PAMAM, PAMAM-3GATG-HA4 and PAMAM-6GATG-HA4 on cell viability within 48 h of MDA-MB-231 cells and MCF-7 cells. Results are expressed as mean ± SD (n = 4). (b) Uptake of nanocomplexes in MDA-MB-231 cells and MCF-7 cells by flow cytometry. FAM-siRNA concentration was 200 nM. In the competition experiments, pre-incubated with free HA was added for incubation. Results are expressed as mean ± SD (n = 3). (c) Laser confocal images used to observe uptake of nanocomplexes in MDA-MB-231 cells. FAM-siRNA concentration was 200 nM. Blue denotes the nucleus and †green denotes FAM-siRNA (scale 25 μm). (d) The lysosomal escape of siRNA after 0.5 and 2 h uptake of PAMAM-6GATG-HA4/siRNA nanocomplexes in MDA-MB-231 cells. FAM-siRNA concentration was 200 nM. Green denotes siRNA and red denotes lysosome (scale 25 μm). Statistical analysis was performed with one-way ANOVA and Bonferroni post-hoc testing with * p < 0.05, ** p < 0.01, and *** p < 0.005.
Figure 4The gene silencing efficacy of PAMAM-GATG-HA4 nanocomplexes analyzed by flow-cytometry and quantitative real-time polymerase chain reaction (qRT-PCR) in MDA-MB-231-GFP cells. The gene silencing efficacy without adding hyaluronan tetrasaccharide was analyzed (a) by flow-cytometry and (b) with adding hyaluronan tetrasaccharide analyzed by flow-cytometry. (c) The gene silencing efficacy without adding hyaluronan tetrasaccharide analyzed by qRT-PCR and (d) with adding hyaluronan tetrasaccharide analyzed by qRT-PCR. Statistical analysis was performed with one-way ANOVA and Bonferroni post-hoc testing with * p < 0.05 and *** p < 0.01. The “negative” represents the blank control group using MDA-MB-231 cells without GFP; the “control” means the MDA-MB-231-GFP cells were not treated with siGFP or nanocomplexes; and the “free” and “lipo” mean the MDA-MB-231-GFP cells were treated with free siGFP or lipofectamine 2000 containing siGFP respectively.